If you have been reading about GHRH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Anti–topoisomerase 1 antibodies, in turn, stimulate type I interferon production. Fibroblasts are recruited and activated by multiple cytokines and growth factors to generate myofibroblasts. Dysregulated transforming growth factor β (TGF-β) signalling in fibroblasts and myofibroblasts has been observed in multiple studies of scleroderma-affected individuals. Activation of fibroblasts and myofibroblasts leads to excessive deposition of collagen and other related proteins, leading to fibrosis. B cells are implicated in this stage, IL-6 and TGF-β produced by the B cells decrease collagen degradation and increase extracellular matrix production. Endothelin signalling is implicated in the pathophysiology of fibrosis. Vitamin D is implicated in the pathophysiology of the disease. An inverse correlation between plasma levels of vitamin D and scleroderma severity has been noted, and vitamin D is known to play a crucial role in regulating (usually suppressing) the actions of the immune system.
=== Classic physique === This is the middle ground of Men's Physique and Bodybuilding, a category that emphasizes symmetry, proportion, pleasing lines, and a small waist over size and mass. The competitors in this category are not nearly as big as Open class bodybuilders but not as small as Men's Physique competitors. They pose and perform in men's boxer briefs or posing trunks to show off the legs as in the Open class, unlike Men's Physique which hide the legs in board shorts. The judging criteria also looks to see certain poses emphasized, such as ones accentuating the vacuum to illustrate a tapered torso and lack of the infamous bloated gut of Open bodybuilding.
== Structure == The ovalbumin protein of chickens consists of 385 amino acids, its relative molecular mass is 42.7 kDa, and it adopts a serpin-like structure. Ovalbumin also has several modifications, including N-terminal acetylation (G1), phosphorylation (S68, S344), and glycosylation (N292). It has three isoforms, A1, A2, and A3, which vary based on the number of bound phosphate residues. It is secreted from the cell, targeted by an internal signal sequence (residues 21–47), rather than the N-terminal signal sequence commonly found in other secreted proteins. Ovalbumin's signal sequence is not cleaved off, but remains as part of the mature protein.
Although a biological joint can resemble a man-made joint in being a hinge or a ball and socket, the engineering problems that nature must solve are very different because the joint works within an almost completely solid structure, with no wheels or nuts and bolts. In general, the bearing surfaces of manmade joints interlock, as in a hinge. This is rare for biological joints (although the badger's jaw interlocks). More often the surfaces are held together by cord-like ligaments. Virtually all the space between muscles, ligaments, bones, and cartilage is filled with pliable solid tissue. The fluid-filled gap is at most only a twentieth of a millimetre thick. This means that synovium has certain jobs to do. These may include:
Sources: en.wikipedia.org
18 March to 28 February 1971 The 196th Light Infantry Brigade and ARVN 5th Regiment, 2nd Division launched Operation Frederick Hill to pacify the coastal areas of Quảng Tín Province. The operation results in 7,514 PAVN/VC killed and 133 captured, U.S. losses are 572 killed.
The agent caused permanent harm, with effects that included "chronic weakness in his arms, a toxic hepatitis that gave rise to cirrhosis of the liver, epilepsy, spells of severe depression, and an inability to read or concentrate that left him totally disabled and unable to work." He never recovered and, after five years of deteriorating health, died in July 1992. The use of a fast-acting peripheral anticholinergic drug such as atropine can block the receptors where acetylcholine acts to prevent poisoning (as in the treatment for poisoning by other acetylcholinesterase inhibitors). Atropine, however, is difficult to administer safely, because its effective dose for nerve agent poisoning is close to the dose at which patients suffer severe side effects, such as changes in heart rate and thickening of the bronchial secretions, which fill the lungs of someone suffering nerve agent poisoning so that suctioning of these secretions, and other advanced life support techniques, may be necessary in addition to administration of atropine to treat nerve agent poisoning. In the treatment of nerve agent poisoning, atropine is most often administered along with a Hagedorn oxime such as pralidoxime, obidoxime, TMB-4, or HI-6, which reactivates acetylcholinesterase which has been inactivated by phosphorylation by an organophosphorus nerve agent and relieves the respiratory muscle paralysis caused by some nerve agents.
== The influence of age: age-structured models == Age has a deep influence on the disease spread rate in a population, especially the contact rate. This rate summarizes the effectiveness of contacts between susceptible and infectious subjects. Taking into account the ages of the epidemic classes
=== Activity against AIDS-associated gut damage === As a result of initial HIV infection, the gut has been found to be a prime center of immune activity. The immune systems' Paneth cells of the gut attack HIV by producing interleukin 1 beta (IL-1β), which results in extensive collateral damage—sloughing of tight intestinal lining, witnessed as severe diarrhea. This destruction of the gut lining allows fungal pathogens to invade, e.g., Cryptococcus species, resulting in an AIDS-defining illness such as cryptococcosis, representing 60% to 70% of all AIDS-defining cases, but not necessarily only the gut. In rhesus macaques, L. plantarum is able to reduce (destroy) IL-1β, resolving inflammation, and accelerating gut repair within hours.
=== Extraction and phase transfer using droplet microfluidics === Liquid-liquid extraction is a method used to separate an analyte from a complex mixture; with this method compounds separate based on their relative solubility in different immiscible liquid phases. To overcome some of the disadvantages associated with common bench top methods such as the shake-flask method, Microfluidic liquid-liquid extraction methods have been employed. Microfluidic droplet-based systems have demonstrated the capability to manipulate discrete volumes of fluids in immiscible phases with low Reynolds numbers. and laminar flow regimes. Microscale methods reduce time required, reduce sample and reagent volume, and allow for automation and integration. In some studies, the performance of droplet-based microfluidic extraction compares closely with the shake-flask method. A study which compared the shake-flask and microfluidic liquid-Liquid extrication methods for 26 compounds and found a close correlation between the values obtained (R2= 0.994). It has also been demonstrated that microfluidic liquid-liquid extraction devices can be integrated with other instruments for detection of the extracted analytes. For example, microfluidic extraction could be used to extract an analyte initially in an aqueous phase such as cocaine in saliva then interfaced with on-chip IR spectroscopy for detection.
Sources: en.wikipedia.org
==== Ingestion ==== While null in comparison to the concentrations found in indoor air, benzene, toluene, and methyl tert-butyl ether (MTBE) were found in samples of human milk and increase the concentrations of VOCs that we are exposed to throughout the day. A study notes the difference between VOCs in alveolar breath and inspired air suggesting that VOCs are ingested, metabolized, and excreted via the extra-pulmonary pathway. VOCs are also ingested by drinking water in varying concentrations. Some VOC concentrations were over the EPA's National Primary Drinking Water Regulations and China's National Drinking Water Standards set by the Ministry of Ecology and Environment.
== Genetics == The gene encoding the enzyme is referred to as DDC is located on chromosome 7 in humans. It consists of 15 exons encoding a protein of 480 amino acids. Single nucleotide polymorphisms and other gene variations have been investigated in relation to neuropsychiatric disorders, for example, a one-base pair deletion at 601 and a four-base pair deletion at 722–725 in exon 1 in relation to bipolar disorder and autism. No direct correlation between gene variation and autism was found. More than 50 mutations of DDC have been correlated with AADC deficiency. This condition is most prevalent in Asia, presumably due to the founder effect. Alternative splicing events and promoters have been observed that lead to various forms of the AADC enzyme. Unique usage of certain promoters leads to transcription of only the first exon to produce an extra-neuronal isoform, and splicing of exon 3 leads to a product devoid of enzymatic activity. Analyses via porcine specimens have elucidated two AADC isoforms – resulting from exclusion of exon 5 and exons 5 and 6 – that lack a portion of the decarboxylating domain.
{\displaystyle {\begin{aligned}[][a_{0},a_{1},a_{2},a_{3}]&=[0.616634218997,0.108855827811,0.023453835635,0.000449332509]\\[][b_{1},b_{2},b_{3},b_{4},b_{5},b_{6}]&=[1.919948267476,1.635304362591,0.799392556572,0.240278859212,0.043178653945,0.003863334276]\end{aligned}}}
Since the early 21st century, the dried fruit, occasionally compared to raisins, has been marketed as a health food, with unsupported health claims about its benefits. In the wake of those claims, dried and fresh goji berries were included in many snack foods and food supplements, such as granola bars. There are products of whole and ground wolfberry seeds and seed oil.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.